Summary
* Pharmaceutical stocks can double your money if you know how to use them.
* Ani Pharmaceuticals is going to greater heights with the recent new drug approvals.
* Adding this stock to your portfolio could be your best decision now.
* Recent Insider Buying proves our forecast to be on track.
Pharmaceutical stocks are great wealth builders. But you need to discover how to use them and what to avoid. Of course, no investment can guarantee you 100% that you will make money all the time, but there are pharmaceutical stocks that can help you make money most of the time.
One such stock that can make you double your money in a short time is ANI Pharmaceuticals Inc (NASDAQ: ANIP). This article will explore the features of the stock and why we are giving it a buy recommendation.
Ani Pharmaceuticals Inc. (NASDAQ: ANIP) develops, markets, and manufactures both branded and generic drugs. Its areas of focus include manufacturing controlled substances, anti-cancer or oncology products, hormones, steroids, and complex formulations. Some of its generic products are Aspirin and extended-release Dipyridamole which is used with Warfarin to prevent blood clotting after heart valve replacements. Also, Cholestyramine prevents bile reabsorption in the intestine for people with high cholesterol and Fluvoxamine, an antidepressant.
Its branded pharmaceutical products are still exclusive and include Arimidex (anastrozole) tablets for treating breast cancer after menopause in women and Cortenema used for treating ulcerative proctitis. Recently, the FDA approved the production of Cortrophin Gel by the company. This drug is used in the treatment of multiple sclerosis and rheumatoid arthritis.
One interesting thing I found about ANIP is its specialized and low-cost operating manufacturing facilities spread across three locations in North America. Two are in Baudette, Minnesota, while the third is in Oakville, Ontario.
Why Ani Pharmaceuticals Will Continue To Generate Value For Shareholders
A worthwhile pharmaceutical stock is constantly releasing new drugs into the market. It takes five years for branded drugs to lose their exclusivity. So for investors to be confident in the company, there needs to be a constant circle of newly released branded and generic medications. Ani Pharmaceuticals has proven to be a gold mine.
The company released a couple of new branded and generic drugs last year, which excited shareholders.
Some include:
Rifabutin Capsules USP, 150 mg: The FDA gave the company approval to manufacture and market Rifabutin Capsules USP. These capsules are the generic listed drugs for the reference drug Mycobutin. Shares of Ani Pharmaceuticals jumped when the news was released in December because the U.S market for the capsules is worth about $20 million. Rifabutin is a drug that slows the spread of Mycobacterium-avium complex disease in people with HIV infections.
Cortrophin Gel: The FDA approved manufacturing supplemental Cortrophin Gel by Ani Pharmaceuticals in August last year. This is a valuable brand product for treating multiple sclerosis, rheumatoid arthritis, and nephrotic syndrome. The annual market of Cortrophin Gel is worth $950 million, and Ani Pharmaceuticals has only one competitor in the market, H.P. Achthar Gel.
Shares of Ani Pharmaceuticals (NASDAQ: ANIP) jumped 16.3% on the news about the approval for Cortrophin Gel.
Recent Insider Trading Activity
Recent news of the insider trading activity in Ani Pharmaceutical stock (NASDAQ: ANIP)also exemplifies that the stock is going to greater heights. There have been several insider trading in the stock. Recently, the company chairman, Patrick Walsh, increased his shares by 10% by buying $139k worth of the stock at US$27.76 per share. This activity increased the price of the stock because insider trading is a reflection of the prospects of a company. In recent times, insiders have not sold any of the stock.
Why Ani Pharmaceuticals Stock Is A Buy For Now
Ani Pharmaceuticals is a buy for now and ranks among the top pharmaceutical stocks to generate enormous profits for holders. This is true because of the recent approvals for new drugs given to the company by the FDA. New drug approvals are signs that a company will receive enormous revenues in the coming years. Ani Pharmaceuticals received more than three last year.
Also, Ani Pharmaceuticals serves a sizeable addressable market for its drugs, especially its recent brand product, Cortrophin gel. Analysts believe this product will give it a considerable boost in revenue this year, and twelve analysts have indicated that they are giving it a buy signal. We are also doing the same. So, now is the time to add ANIP to your portfolio to boost your investments. ANIP is currently sitting at 27.97 USD.
Rate this article